Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene pulls EU Revlimid application as CHMP seeks follow-up cancer data

This article was originally published in Scrip

Executive Summary

Celgene has withdrawn its European application to have its blood cancer drug Revlimid (lenalidomide) approved for maintenance use in newly diagnosed patients with multiple myeloma – an expanded use - after EU regulators made it clear that additional follow-up was needed from three ongoing studies in the submission with respect to the treatment's links to second primary malignancies. They claim they need this mature data to make a clear benefit-risk decision.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts